Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Change in Acquisitions & Divestments (2021 - 2025)

Kezar Life Sciences' Change in Acquisitions & Divestments history spans 5 years, with the latest figure at $30.0 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 31.9% year-over-year to $30.0 million; the TTM value through Sep 2025 reached $126.5 million, down 38.77%, while the annual FY2024 figure was $171.8 million, 33.48% down from the prior year.
  • Change in Acquisitions & Divestments for Q3 2025 was $30.0 million at Kezar Life Sciences, down from $39.7 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $85.2 million in Q4 2022 and bottomed at $13.8 million in Q1 2025.
  • The 5-year median for Change in Acquisitions & Divestments is $43.8 million (2021), against an average of $46.5 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 358.26% in 2023 before it tumbled 63.58% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $31.0 million in 2021, then surged by 175.0% to $85.2 million in 2022, then dropped by 8.8% to $77.8 million in 2023, then crashed by 44.71% to $43.0 million in 2024, then plummeted by 30.22% to $30.0 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Change in Acquisitions & Divestments are $30.0 million (Q3 2025), $39.7 million (Q2 2025), and $13.8 million (Q1 2025).